{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:42:02Z","timestamp":1789062122504,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gynecology Obstetrics and Human Reproduction"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jgyn.2016.04.002","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T06:31:38Z","timestamp":1464417098000},"page":"87-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome"],"prefix":"10.1016","volume":"46","author":[{"given":"S.","family":"Jellad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Haj Hassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Basly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mrabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rachdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgyn.2016.04.002_bib0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/molehr\/8.5.409","article-title":"The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome","volume":"8","author":"Albert","year":"2002","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10815-010-9387-6","article-title":"Ovarian hyperstimulation syndrome pathophysiology and prevention","volume":"27","author":"Nastri","year":"2010","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0090","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1210\/en.2006-0657","article-title":"Low dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model","volume":"147","author":"Gomez","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0095","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1093\/humrep\/dem315","article-title":"Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study","volume":"22","author":"Alvarez","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mefs.2010.10.004","article-title":"Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome","volume":"16","author":"Soliman","year":"2011","journal-title":"Middle East Fertil Soc J"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0105","first-page":"837","article-title":"Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study","volume":"11","author":"Torabizadeh","year":"2013","journal-title":"Iran J Reprod Med"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0110","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0115","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","article-title":"Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study","volume":"17","author":"Carriza","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0120","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1055\/s-0030-1265670","article-title":"Physiology and pathology of ovarian hyperstimulation syndrome","volume":"28","author":"Gomez","year":"2010","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0125","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/00016341003592537","article-title":"Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparaison between cabergoline and meloxicam","volume":"89","author":"Saylan","year":"2010","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0130","first-page":"35","article-title":"Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients","volume":"3","author":"Sohrabvand","year":"2009","journal-title":"Int J Fertil"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijgo.2009.09.017","article-title":"Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels","volume":"108","author":"Hwang","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0140","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/humupd\/dmq006","article-title":"Review can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis","volume":"16","author":"Youssef","year":"2010","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10815-011-9708-4","article-title":"Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial","volume":"29","author":"Tehraninejad","year":"2012","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.jgyn.2016.04.002_bib0150","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/humrep\/deg451","article-title":"Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high risk IV F patients: a randomized controlled study","volume":"18","author":"Belver","year":"2003","journal-title":"Hum Reprod"}],"container-title":["Journal of Gynecology Obstetrics and Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0368231516300291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0368231516300291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T21:49:11Z","timestamp":1635716951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0368231516300291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0368231516300291"],"URL":"https:\/\/doi.org\/10.1016\/j.jgyn.2016.04.002","relation":{},"ISSN":["2468-7847"],"issn-type":[{"value":"2468-7847","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Gynecology Obstetrics and Human Reproduction","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgyn.2016.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}